Safety of and Immune Response to a Bird Flu Virus Vaccine (H9N2) in Healthy Adults (Study A)

Inclusion Criteria: * Born after 1968 * Good general health * Available for the duration of the trial Exclusion Criteria: * Clinically significant neurologic, cardiac, pulmonary, hepatic, rheumatologic, autoimmune, or renal disease * Behavioral, cognitive, or psychiatric disease that, in the opinion of the investigator, affects the ability of the volunteer to understand and cooperate with the study * Liver, renal, or hematologic disease * Alcohol or drug abuse within 12 months of study entry * History of severe allergic reaction or anaphylaxis * Current asthma or reactive airway disease * History of Guillain-Barre syndrome * HIV-1 infected * Hepatitis C virus infected * Positive for hepatitis B surface antigen (HBsAg) * Known immunodeficiency syndrome * Use of corticosteroids or immunosuppressive drugs within 30 days of study entry. Participants who have used topical corticosteroids are not excluded. * Live vaccine within 4 weeks of study entry * Killed vaccine within 2 weeks of study entry * Absence of spleen * Blood products within 6 months of study entry * Current smoker * Have traveled to the Southern Hemisphere or Asia within 30 days prior to study entry * Have traveled on a cruise ship within 30 days prior to study entry * Work in the poultry industry * Investigational agents within 60 days prior to study entry, or currently participating in another investigational vaccine or drug trial * Allergy to eggs or egg products * Purified protein derivative (PPD) positive (p…